Benefit-risk of VKA for atrial fibrillation before doac: a cohort study in a claims and Hospitalization database

Benefit-risk of VKA for atrial fibrillation before doac: a cohort study in a claims and Hospitalization database

Background Vitamin K antagonists (VKA) are a major iatrogenic cause of haemorrhage and hospital admissions, but the incidence of bleeding during VKA exposure for atrial fibrillation (AF), as well as ischemic event, is not well established in real life and before introduction of direct oral anticoagu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical therapeutics 2015-08, Vol.37 (8), p.e11-e11
Hauptverfasser: Blin, P, Dureau-Pournin, C, Lassalle, R, Abouelfath, A, Droz-Perroteau, C, Moore, N
Format: Artikel
Sprache:eng
Schlagworte:
Acute coronary syndromes
Cardiology
Hospitalization
Internal Medicine
Medical Education
Population
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Vitamin K antagonists (VKA) are a major iatrogenic cause of haemorrhage and hospital admissions, but the incidence of bleeding during VKA exposure for atrial fibrillation (AF), as well as ischemic event, is not well established in real life and before introduction of direct oral anticoagulants (DOAC) for non-valvular AF (NVAF).
ISSN:0149-2918
1879-114X
DOI:10.1016/j.clinthera.2015.05.041